About Novyra Pharmachem Limited
Data last updated:
Novyra Pharmachem Limited is a public limited company based in Surat, Gujarat, India. It operates in the tea and coffee processing segment of the agriculture sector. It was incorporated on 08 September 1987 and has been in existence for over 39 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L21001GJ1987PLC171085. It is a listed company as per MCA records. Its shares are listed on BSE: 519353.
The company has an authorised share capital of ₹6.5 Cr and a paid-up capital of ₹6.33 Cr. It was formerly known as Bansisons Beverages Private Limited. It is led by directors including Sandeep Agarwal (Whole-Time Director) and Amit Mitruka.
Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Surat, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹10 Lakh. For the same year it recorded a net loss of ₹5.38 Cr and EBITDA of -₹5.41 Cr. The net worth stands at ₹62 Lakh (down 89.7% YoY). Total assets are valued at ₹62 Lakh (down 89.7% YoY).
As per MCA filings, the company has satisfied charges of ₹50 Lakh on record. Court records list 11 cases involving the company, including 9 filed by the company and 2 filed against it; 1 case is pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bansisonstea.in.
Company details
Name history
Novyra Pharmachem has undergone 2 name changes throughout its history. The company was previously known as Bansisons Beverages Private Limited, and Novyra Pharmachem Limited. The current legal name is Novyra Pharmachem Limited.
| Company Name | Status |
|---|---|
| Novyra Pharmachem Limited | Current |
| Bansisons Beverages Private Limited | Previous |
CIN history
Novyra Pharmachem has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L21001GJ1987PLC171085, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L21001GJ1987PLC171085 | Current |
| U15520WB1987PLC042982 | Previous |
| L15520WB1987PLC042982 | Previous |
Contact details
Novyra Pharmachem Limited's registered office is in Surat, Gujarat.
- Registered AddressR S No 432 T P Scheme No 3 F P No 89/A City Survey No 3763 Plot No C Palky Plot No A, Ground Floor Back Side Pavthawala Compound B/H Zenith Mill Vastadevadi Road, Surat, Gujarat, India – 395004
- IndustryAgriculture, Tea & Coffee Processing
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Novyra Pharmachem Limited
FY 2025-26 filings availableNovyra Pharmachem Limited reported revenue of ₹10 Lakh for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.10 | 0.00 | 0.00 | 0.15 | 0.15 | 0.15 | 0.15 |
| Revenue growth | - | - | -100.0% | 0.0% | 0.0% | 0.0% | - |
| EBITDA | (5.41) | (0.08) | (0.15) | 0.05 | (0.02) | 0.06 | 0.01 |
| EBITDA margin | -5410.0% | - | - | +33.3% | -13.3% | +40.0% | +6.7% |
| Profit before tax | (5.38) | (0.06) | (0.17) | 0.04 | 0.00 | 0.09 | (0.01) |
| Net profit | (5.38) | (0.06) | (0.17) | 0.02 | 0.00 | 0.08 | (0.01) |
| Net profit margin | -5380.0% | - | - | +13.3% | 0.0% | +53.3% | -6.7% |
| EPS (₹) | (8.49) | (0.10) | (0.26) | 0.02 | 0.01 | 0.13 | (0.03) |
| Balance sheet | |||||||
| Total assets | 0.62 | 6.00 | 6.03 | 6.19 | 6.17 | 6.17 | 5.99 |
| Net worth | 0.62 | 6.00 | 5.93 | 6.09 | 6.08 | 6.07 | 6.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.18 | 0.26 | 0.08 | 0.22 | 0.08 | 0.11 | 0.07 |
| Net working capital | (0.11) | 0.14 | 0.14 | 0.31 | 0.14 | 0.15 | 0.05 |
| Cash flow | |||||||
| Cash from operations | (3.79) | (0.28) | (0.14) | 0.14 | (0.06) | (0.02) | 0.01 |
| Cash from investing | 3.85 | 0.18 | 0.00 | 0.01 | 0.03 | 0.05 | (0.12) |
| Cash from financing | (0.15) | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.05 | 0.00 | 0.00 |
| Total expenses | 1.74 | 5.44 | 0.02 | 0.00 | 0.03 | 0.06 | 0.01 | 0.00 |
| EBITDA | (0.01) | (5.34) | (0.02) | 0.00 | (0.03) | (0.06) | (0.01) | 0.00 |
| EBITDA margin | -0.6% | -5340.0% | - | - | - | - | - | - |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.01) | (5.35) | (0.03) | 0.01 | (0.01) | (0.04) | (0.01) | 0.00 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.05 | 0.00 | 0.00 |
| Total expenses | 1.74 | 5.44 | 0.02 | 0.00 | 0.03 | 0.06 | 0.01 | 0.00 |
| EBITDA | (0.01) | (5.34) | (0.02) | 0.00 | (0.03) | (0.06) | (0.01) | 0.00 |
| EBITDA margin | -0.6% | -5340.0% | - | - | - | - | - | - |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.01) | (5.35) | (0.03) | 0.01 | (0.01) | (0.04) | (0.01) | 0.00 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.00 | 0.00 | 0.15 | 0.15 | 0.15 | 0.15 |
| Revenue growth | - | - | -100.0% | 0.0% | 0.0% | 0.0% | - |
| Other income | 0.06 | 0.05 | 0.00 | 0.01 | 0.04 | 0.05 | 0.00 |
| Total expenses | 5.51 | 0.08 | 0.15 | 0.10 | 0.17 | 0.09 | 0.14 |
| Employee cost | 0.15 | 0.04 | 0.03 | 0.04 | 0.05 | 0.03 | 0.03 |
| EBITDA | (5.41) | (0.08) | (0.15) | 0.05 | (0.02) | 0.06 | 0.01 |
| EBITDA margin | -5410.0% | - | - | +33.3% | -13.3% | +40.0% | +6.7% |
| Depreciation | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (5.38) | (0.06) | (0.17) | 0.04 | 0.00 | 0.09 | (0.01) |
| Tax | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.01 | 0.00 |
| Net profit | (5.38) | (0.06) | (0.17) | 0.02 | 0.00 | 0.08 | (0.01) |
| Net profit margin | -5380.0% | - | - | +13.3% | 0.0% | +53.3% | -6.7% |
| EPS (₹) | (8.49) | (0.10) | (0.26) | 0.02 | 0.01 | 0.13 | (0.03) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.33 | 6.33 | 6.20 | 6.20 | 6.20 | 6.20 | 6.20 |
| Reserves & surplus | (5.71) | (0.33) | (0.27) | (0.11) | (0.12) | (0.13) | (0.20) |
| Shareholders' funds (net worth) | 0.62 | 6.00 | 5.93 | 6.09 | 6.08 | 6.07 | 6.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 0.62 | 6.00 | 6.03 | 6.19 | 6.17 | 6.17 | 5.99 |
| Assets | |||||||
| Gross block | 0.74 | 5.67 | 5.77 | 5.77 | 5.77 | 5.76 | 5.76 |
| Net block | 0.74 | 4.93 | 5.06 | 5.08 | 5.10 | 5.11 | 5.13 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 0.01 | 0.06 | 0.14 | 0.14 | 0.08 | 0.06 | 0.07 |
| Cash & bank balances | 0.18 | 0.26 | 0.08 | 0.22 | 0.08 | 0.11 | 0.07 |
| Loans & advances | 0.56 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.00 |
| Total current assets | 0.75 | 0.32 | 0.23 | 0.37 | 0.18 | 0.20 | 0.14 |
| Total current liabilities | 0.86 | 0.18 | 0.09 | 0.06 | 0.04 | 0.05 | 0.09 |
| Net working capital | (0.11) | 0.14 | 0.14 | 0.31 | 0.14 | 0.15 | 0.05 |
| Total assets | 0.62 | 6.00 | 6.03 | 6.19 | 6.17 | 6.17 | 5.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.26 | 0.09 | 0.22 | 0.08 | 0.11 | 0.07 | 0.18 |
| Net cash from operating activities | (3.79) | (0.28) | (0.14) | 0.14 | (0.06) | (0.02) | 0.01 |
| Net cash from investing activities | 3.85 | 0.18 | 0.00 | 0.01 | 0.03 | 0.05 | (0.12) |
| Net cash from financing activities | (0.15) | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net change in cash | (0.09) | 0.18 | (0.14) | 0.14 | (0.03) | 0.03 | (0.11) |
| Closing cash | 0.18 | 0.26 | 0.08 | 0.22 | 0.08 | 0.11 | 0.07 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | - | - | -100.0% | 0.0% | 0.0% | 0.0% | - |
| EBITDA growth | -6662.5% | +46.7% | -400.0% | +350.0% | -133.3% | +500.0% | - |
| PBT growth | -8866.7% | +64.7% | - | +9997.0% | +9997.0% | +9998.0% | +92.3% |
| Net income growth | -8866.7% | +64.7% | -950.0% | - | -100.0% | +900.0% | - |
| Revenue CAGR (3Y) | -12.6% | -100.0% | -100.0% | 0.0% | -55.7% | -55.7% | -53.6% |
| EBITDA CAGR (3Y) | - | +58.7% | - | +71.0% | -43.4% | +81.7% | -51.9% |
| Profitability & leverage | |||||||
| Net income margin | -5380.0% | - | - | +13.3% | 0.0% | +53.3% | -6.7% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | +0.5% | 0.0% | +1.5% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | +0.2% | 0.0% | +1.3% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.03 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 2.86 | 0.00 | 0.00 | 1.36 | 2.14 | 2.31 | 1.36 |
| EPS (₹) | (8.49) | (0.10) | (0.26) | 0.02 | 0.01 | 0.13 | (0.03) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.98 | 9.47 | 9.56 | 9.82 | 9.80 | 9.80 | 9.67 |
To see the full year-wise statements and ratios of Novyra Pharmachem Limited, buy the company report.
Board of directors of Novyra Pharmachem Limited
Novyra Pharmachem has 6 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amit Mitruka Also directs: Sunflower Vanijya Private Limited, Sinhal Realtors Private Limited | Director | 07 Sep 2021 | 5 Years 1 Months | Current |
| Sandeep Agarwal Also directs: Ruchi Valley LLP, Eversafe Developers LLP, Siliguri Heights Private Limited and 5 more | Whole-Time Director | 18 Jun 2001 | 25 Years 4 Months | Current |
| Sushilaben Dipakkumar Shah | Director | 16 Mar 2024 | 2 Years 7 Months | Current |
| Chirag Kirtikumar Nanavati Also directs: Devrup Trading Limited | Director | 16 Mar 2024 | 2 Years 7 Months | Current |
| Hiren Dhirajlal Shah Also directs: Jamnagar Copper Alloy Components LLP, Sky Tone Logistic Park LLP, Festino Vincom Limited and 2 more | Director | 11 Sep 2024 | 2 Years 1 Months | Current |
| Anilkumar Mohanbhai Amreliya | Additional Director | 06 Feb 2026 | 0 Years 8 Months | Current |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Feb 1998 | 90252750 | State Bank of Bikaner and Jaipur | ₹50 Lakh | Satisfied |
To see the full charge records of Novyra Pharmachem Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Novyra Pharmachem Limited has 11 court cases on record: 9 filed by Novyra Pharmachem, 2 filed against it. 1 case is pending and 10 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 10 | 2 | 1 |
| High courts | 1 | 0 | 0 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Jalpaiguri, West Bengal | Civil suit | Filed by the company against Ms Aasu Exports and Marketing Pvt Ltd and 1 other | Disposed |
| District court, Jalpaiguri, West Bengal | Civil suit | Filed by the company against Ms Aasu Projects Pvt Ltd and 1 other | Disposed |
| District court, Jalpaiguri, West Bengal | Civil suit | Filed by the company against an individual | Pending |
| District court, Jalpaiguri, West Bengal | Civil suit | Filed by the company against Ms Bengal Mega Food Park Ltd and 1 other | Disposed |
| District court, Jalpaiguri, West Bengal | Civil suit | Filed by the company against Ms Aasu Exports and Marketing and 1 other | Disposed |
To see the full case history of Novyra Pharmachem Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Novyra Pharmachem Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Novyra Pharmachem Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Novyra Pharmachem Limited has 22 board changes on record since 2001: 7 appointments and 15 cessations. The latest: Anilkumar Mohanbhai Amreliya was appointed as Additional Director on 06 Feb 2026.
16 earlier events are in the company report.
News
Frequently asked questions
Novyra Pharmachem is an active public limited company based in Surat, Gujarat, India. The company works in tea and coffee processing, within the agriculture industry. It was incorporated on 08 September 1987 (39+ years old) and is registered under CIN L21001GJ1987PLC171085. Listed on BSE: 519353.
Novyra Pharmachem reported revenue of ₹10 Lakh for FY 2025-26 based on standalone financials.
Novyra Pharmachem has 6 current directors:
- Sandeep Agarwal - Whole-Time Director
- Amit Mitruka - Director
- Sushilaben Dipakkumar Shah - Director
- Chirag Kirtikumar Nanavati - Director
- Hiren Dhirajlal Shah - Director
- Anilkumar Mohanbhai Amreliya - Additional Director
The latest financial statements of Novyra Pharmachem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Novyra Pharmachem is L21001GJ1987PLC171085. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Novyra Pharmachem is a listed company as per MCA records. Its shares are listed on BSE (code: 519353).
Novyra Pharmachem has 11 court cases on record: 9 filed by the company and 2 filed against it. 1 is pending. Most are in the district courts.
Novyra Pharmachem was incorporated on 08 September 1987, making it 39+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Anilkumar Mohanbhai Amreliya was appointed as Additional Director on 06 Feb 2026. Hiren Dhirajlal Shah ceased to be Additional Director on 23 Mar 2025. Chirag Kirtikumar Nanavati ceased to be Additional Director on 29 Sep 2024. Novyra Pharmachem has 22 board changes on record in total.
Novyra Pharmachem can be reached through the website bansisonstea.in. Its registered office is in Surat, Gujarat, India.